Arpida’s Novel Anti-Infective Iclaprim Buoyed By Second Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss firm plans regulatory submission in the U.S. by the end of the year, launch in 2008.
You may also be interested in...
Arpida Files NDA For Intravenous Anti-infective Iclaprim
Swiss firm seeks priority review for its novel anti-infective candidate in complicated skin, skin structure infections.
Arpida Files NDA For Intravenous Anti-infective Iclaprim
Swiss firm seeks priority review for its novel anti-infective candidate in complicated skin, skin structure infections.
Arpida’s Iclaprim Labeling Would Likely Include QTc Language
Firm plans to file an NDA for the Zyvox competitor in 2007 and launch in 2008.